In addition, aberrant expression of p16INK4a may be a marker for ERα negative breast cancers such as the TNBC and HER2-enriched subtypes, and may also be useful in distinguishing HER2-enriched from Luminal-B-HER2 positive breast tumors. Here, CDKN2A is linked to breast neoplasm.